Apposite Capital

Mirada Medical Limited specializes in the development of medical imaging software applications tailored for radiology, molecular imaging, radiation oncology, and multidisciplinary meetings in hospitals, imaging centers, and cancer centers. Founded in 1999 and headquartered in Oxford, United Kingdom, with an additional office in Denver, Colorado, the company offers a range of innovative software solutions. These include Mirada XD, which serves various medical fields such as nuclear medicine and cardiology; DLCExpert, a clinical application that provides automated organ-at-risk contouring; and Mirada IM, which supports interventional medicine products, including radioembolization therapy. Mirada Medical's products are marketed through direct sales and distributors, aiming to enhance the diagnosis, management, and treatment of cancer and other diseases worldwide.

1Med is a contract research organization (CRO) that provides a comprehensive range of clinical research services tailored to meet the needs of clinical trials. The company specializes in regulatory strategy, clinical trial management, and quality assurance, supporting businesses throughout the entire product lifecycle. This includes services from initial design and development to certification, covering regulatory, medical, preclinical, and clinical aspects. By offering these integrated solutions, 1Med enables organizations to maintain essential internal competencies and effectively achieve their objectives in the complex landscape of clinical research.

Archway Dental Practice Limited, established in 1996, offers dental services primarily to private patients in Dursley and Stroud, United Kingdom. The practice has been delivering quality dental care for over 15 years and caters to both NHS and private patients. Headquartered in Dursley, the company has positioned itself as a trusted provider of dental services in the local community. As of September 2019, Archway Dental Practice Limited operates as a subsidiary of Riverdale Healthcare Limited.

Mirada Medical Limited specializes in the development of medical imaging software applications tailored for radiology, molecular imaging, radiation oncology, and multidisciplinary meetings in hospitals, imaging centers, and cancer centers. Founded in 1999 and headquartered in Oxford, United Kingdom, with an additional office in Denver, Colorado, the company offers a range of innovative software solutions. These include Mirada XD, which serves various medical fields such as nuclear medicine and cardiology; DLCExpert, a clinical application that provides automated organ-at-risk contouring; and Mirada IM, which supports interventional medicine products, including radioembolization therapy. Mirada Medical's products are marketed through direct sales and distributors, aiming to enhance the diagnosis, management, and treatment of cancer and other diseases worldwide.

Prime Health Diagnostics Ltd operates as a diagnostic, treatment, and fitness facility. It offers medical and diagnostics services, such as consultant clinics, private GP, 3T MRI, ultrasound, and X-ray; and therapy and fitness services, including physiotherapy and osteopathy, personal training, Pilates, nutritional therapy, podiatry, sports massage, performance coaching, and complementary therapy. The company was incorporated in 2010 and is based in Weybridge, United Kingdom.

OrthoD Group, now known as Summit Medical Group Limited, is a manufacturer and distributor of medical products specializing in joint reconstruction and sports medicine. The company produces a range of medical devices, including surgical products, sports medicine implants, and accessories for infection control. Its offerings include reconstruction devices, autologous blood transfusion systems, bone cement and delivery systems, exsanguinating sterile tourniquets, and wound drains. Founded in 1984 and based in Cheltenham, United Kingdom, the company also operates in France, serving various medical needs through its innovative products.

Swanton, a specialist provider of residential and supported living care for adults with complex learning disabilities, mental health disorders and acquired brain injuries. Swanton operates 24 specialist residential care homes, providing 259 registered beds across East Anglia, The West Midlands and South West Wales, the North East and Scotland. Swanton also provides a growing supported living service in its key localities. The company employs around 780 people and generated £25m revenues in the year end.

NIMGenetics is an authorized analytical diagnostic center specializing in genetic testing, located in Madrid. The center is staffed by a team of accredited scientific and medical professionals recognized by the Spanish Association of Human Genetics. NIMGenetics focuses on developing and applying high-resolution genomic systems for reliable and precise clinical diagnoses. Utilizing advanced genomic technologies, including next-generation sequencing and microarray technology, NIMGenetics provides medical genetic diagnosis across various medical fields such as gynecology, neurology, pediatrics, and oncology. This enables healthcare providers to enhance patient care and improve health outcomes for individuals with genetic disorders.

Enara provides high quality home care in the UK, delivering a wide range of services to people who require help and support due to illness, disability or infirmity. The business cares for people via local authority, NHS and private pay agreements.

Complete Care specializes in delivering high acuity healthcare services at home for individuals with complex clinical needs across England and Wales. The organization serves approximately 150 patients, offering rehabilitative support and care for conditions such as cerebral palsy, motor neuron diseases, and muscular dystrophy. Employing around 650 personal care assistants, including registered nurses, Complete Care aims to enhance the health and well-being of its patients while enabling them to receive care in the comfort of their own homes. This focus on home-based care aligns with and complements the existing domiciliary care operations in the region.

MiHomecare provide a wide range of homecare services to people who need help and support, whether due to old age, illness, disability or infirmity.

Medical Imaging Partnership is a UK-based provider of high-quality radiology services, designed to serve both private patients and those within the NHS. Established by UK radiologists, the organization aims to deliver fast access to expert-led services for patients and referrers alike. It offers a comprehensive range of fully managed clinical services, including MRI, CT, ultrasound, X-ray, dual-energy X-ray absorptiometry scans, and ultrasound-guided steroid injections. By ensuring that reports are generated by leading specialist radiologists, Medical Imaging Partnership provides an unparalleled service to healthcare professionals and patients. The organization is accredited by major private medical insurers and also offers competitive self-pay pricing options.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Cancer Partners UK is a provider of cancer treatment services that operates a network of purpose-built cancer centres throughout the United Kingdom. Each centre is uniquely designed to cater to the specific needs of its local community and offers a variety of services, including diagnostics, chemotherapy, radiotherapy, and palliative care. The organization emphasizes patient-focused care, ensuring that from the initial referral by a general practitioner, patients have prompt access to necessary diagnostic procedures and comprehensive treatment options, all available in one location. By maintaining high standards across its centres, Cancer Partners UK aims to deliver consistent, high-quality care to individuals facing cancer.

Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.

Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.

Ulthera is a medical technology company focused on developing non-invasive ultrasound-based devices for aesthetic procedures. The company aims to meet the growing demand for effective and safe rejuvenation treatments by leveraging its patented DeepSEE technology, which integrates imaging and therapy capabilities of traditional medical ultrasound. Ulthera's journey began with research into image-guided cancer therapy, evolving over seven years into a dedicated effort to enhance aesthetic medical practices. By addressing the unmet needs in the aesthetic market, Ulthera seeks to deliver consistent and satisfying results for skin rejuvenation and underlying tissue treatment.

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (“GSK”). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels.

SureCalm Healthcare specializes in delivering high-quality homecare services to patients managing long-term chronic conditions. The company offers a comprehensive range of healthcare solutions tailored to individual needs, including the dispensing of stoma care and continence devices, as well as home delivery services. Additionally, SureCalm has recently launched an internet and mail order pharmacy, which provides clients with essential medications and expert advice. This focus on personalized care and accessibility positions SureCalm as a significant player in the homecare sector.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

PharmaKodex is a pharmaceutical company that develops and commercializes small molecule drugs for treating pain and neurological conditions. The company was founded in 2006 and is based in Cambridge, the United Kingdom with an additional office in Chippenham, the United Kingdom. As of February 23, 2009, PharmaKodex Ltd. operates as a subsidiary of Orexo AB.

Ambrx is a biopharmaceutical company headquartered in La Jolla, California, that specializes in developing engineered precision biologics using a proprietary technology platform to incorporate synthetic amino acids into proteins. The company focuses on creating protein therapeutics that enhance potency, reduce dosing frequency, and improve drug homogeneity. Its development pipeline includes antibody drug conjugates (ADCs), bi-specific product candidates, and long-acting protein therapeutics, alongside various early-stage programs. Ambrx has established collaborations with MabSpace Biosciences for ADC development in oncology, BeiGene for the commercialization of biologic drugs, and NovoCodex Biopharmaceuticals for the advancement of ARX305, an ADC targeting CD70 positive cancers. Founded in 2003, the company aims to innovate and expand the capabilities of biologic therapies.